Literature DB >> 3830521

Gastrointestinal function in patients with progressive systemic sclerosis.

A Akesson, B Akesson, T Gustafson, F Wollheim.   

Abstract

In 24 patients with progressive systemic sclerosis (PSS) the pentagastrin-stimulated gastric acid secretion was determined to investigate if acid hypersecretion is associated with reflux-oesophagitis--the most common complication to oesophageal involvement in PSS. Gastro-oesophageal reflux was observed in 12, reflux-oesophagitis in 9 and oesophageal mycosis in 8 patients. Gastric acid secretion was increased in 13 (54%) patients and tended to be higher in patients with oesophagitis. Patients with reflux and increased acid secretion seemed to be free from oesophageal mycosis. Bacterial overgrowth and malabsorption are known complications to intestinal scleroderma and these items were investigated using non-invasive methods. Four patients had increased bile acid deconjugation, 3 had increased (14C)xylose degradation indicating bacterial overgrowth and 7 patients had decreased fat absorption in the triolein breath test. Nutritional status with respect to selenium, folate, cobalamin and fat-soluble vitamins was essentially normal.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3830521     DOI: 10.1007/bf02031897

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  25 in total

1.  Malabsorption in intestinal scleroderma. Relation to bacterial flora and treatment with antibiotics.

Authors:  G Salen; F Goldstein; C W Wirts
Journal:  Ann Intern Med       Date:  1966-04       Impact factor: 25.391

2.  Small intestine bacterial overgrowth.

Authors:  C E King; P P Toskes
Journal:  Gastroenterology       Date:  1979-05       Impact factor: 22.682

Review 3.  Gastrointestinal hormones in the pathogenesis of peptic ulcer disease.

Authors:  I L Taylor
Journal:  Clin Gastroenterol       Date:  1984-05

4.  Effect of esophageal emptying and saliva on clearance of acid from the esophagus.

Authors:  J F Helm; W J Dodds; L R Pelc; D W Palmer; W J Hogan; B C Teeter
Journal:  N Engl J Med       Date:  1984-02-02       Impact factor: 91.245

5.  An improved coupled test procedure for glutathione peroxidase (EC 1-11-1-9-) in blood.

Authors:  W A Günzler; H Kremers; L Flohé
Journal:  Z Klin Chem Klin Biochem       Date:  1974-10

6.  [Gastrin level in the blood serum of patients with systemic scleroderma].

Authors:  E N Kochina; A L Grebenev; N N Napalkova; L I Tsvetkova; V S Ioffe
Journal:  Ter Arkh       Date:  1981       Impact factor: 0.467

7.  Interdigestive motor activity in patients with systemic sclerosis.

Authors:  W D Rees; R J Leigh; N D Christofides; S R Bloom; L A Turnberg
Journal:  Gastroenterology       Date:  1982-09       Impact factor: 22.682

8.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.

Authors: 
Journal:  Arthritis Rheum       Date:  1980-05

9.  The gastrointestinal manifestations of scleroderma: pathogenesis and management.

Authors:  S Cohen
Journal:  Gastroenterology       Date:  1980-07       Impact factor: 22.682

10.  Clinical value of the bile acid breath test. Evaluation of the Mayo Clinic experience.

Authors:  B H Lauterburg; A D Newcomer; A F Hofmann
Journal:  Mayo Clin Proc       Date:  1978-04       Impact factor: 7.616

View more
  3 in total

1.  Dietary intake and nutritional status in patients with systemic sclerosis.

Authors:  A C Lundberg; A Akesson; B Akesson
Journal:  Ann Rheum Dis       Date:  1992-10       Impact factor: 19.103

2.  Gastrointestinal transit times of radiolabeled meal in progressive systemic sclerosis.

Authors:  J L Madsen; L Hendel
Journal:  Dig Dis Sci       Date:  1992-09       Impact factor: 3.199

Review 3.  Points to consider for clinical trials of the gastrointestinal tract in systemic sclerosis.

Authors:  Daniel E Furst; Yolanda Braun-Moscovic; Dinesh Khanna
Journal:  Rheumatology (Oxford)       Date:  2017-09-01       Impact factor: 7.580

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.